Amyotrophic lateral sclerosis: A clinical review

A neurodegenerative disease of the motor pathways, amyotrophic lateral sclerosis (ALS) always results in death within a few years of start. 10% of ALS cases are familial variants of the illness (FALS), while the majority of ALS cases are sporadic. More than 20 genes have been connected to FALS since the 1990s, when a causal gene was initially discovered, and thanks to current developments in genetics. Both proximally and distally in the upper and lower limbs, localized muscular weakness and wasting are symptoms that are present in about two-thirds of people with typical ALS who have the spinal form of the disease (limb onset). Spasticity may gradually develop in the weaker atrophic limbs, impairing walking and manual dexterity. Most patients with bulbar onset ALS will experience symptoms in the limbs within 1-2 years after developing bulbar symptoms, which often include dysarthria and dysphagia for solids or liquids. Although the exact causes of amyotrophic lateral sclerosis are unknown, numerous environmental risk factors and several genes that have been found to contain disease-associated mutation are among them. The nature, epidemiology, genetic correlations, and environmental exposures linked to amyotrophic lateral sclerosis are reviewed here. Although the exact causes of amyotrophic lateral sclerosis are unknown, numerous environmental risk factors and several genes that have been found to contain disease-associated mutation are among them. The nature, epidemiology, genetic correlations, and environmental exposures linked to amyotrophic lateral sclerosis are reviewed here.